Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity
Posted on Thu, Sep 08, 2011
Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity: Randomized Controlled Trial
Pediatrics, 09/08/2011
Imhoff–Kunsch B et al. – Docosahexaenoic acid (DHA) supplementation during pregnancy decreased the occurrence of colds in children at 1 month and influenced illness symptom duration at 1, 3, and 6 months.
Methods
- In a double-blind randomized controlled trial conducted in Mexico, pregnant women received daily supplementation with 400 mg of DHA or placebo from 18 to 22 weeks' gestation through parturition.
- In infants aged 1, 3, and 6 months, caregivers reported the occurrence of common illness symptoms in the preceding 15 days.
Results
- Data were available at 1, 3, and 6 months for 849, 834, and 834 infants, respectively.
- The occurrence of specific illness symptoms did not differ between groups; however, the occurrence of a combined measure of cold symptoms was lower in the DHA group at 1 month. At 1 month, the DHA group experienced 26%, 15%, and 30% shorter duration of cough, phlegm, and wheezing, respectively, but 22% longer duration of ...read more
Read all
Pediatrics articles at
MDLinx.com